Susan Evans‐Axelsson

Author

Also Known As

Evans-Axelsson, Susan, S. Evans, S. Evans-Axelsson, S.E. Axelsson, Susan Evans, Susan Evans Axelsson, Susan Evans-Axelsson, Susan Evans‐Axelsson, Susan L. Evans-Axelsson

Publications

703

Citations

H-Index

Concepts

All Affiliations

Lund University Skåne University Hospital University of California, Los Angeles University of Oxford Malmö University

About

Susan Evans‐Axelsson is an author at Lund University specializing in tumor biology, urology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	122
2	Engineering	1	1	35
3	Health Sciences	1	1	35
4	Cell Biology	1	1	73
5	Pathology	1	1	73

Susan Evans‐Axelsson

Publications

529

Citations

H-Index

Page 1

	Year	Citations
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer Katharina Lückerath, Wei Liu, Wolfgang P. Fendler, EJNMMI Research	2018	85
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model Giacomo Canesin, Susan Evans‐Axelsson, Rebecka Hellsten, PLoS ONE High Wnt5a ExpressionUrologyMetastatic SpreadWnt5a-mimicking Peptide Foxy-5Medicine	2017	73
Establishing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer Wolfgang P. Fendler, Andreea D. Stuparu, Susan Evans‐Axelsson, Journal of Nuclear Medicine	2017	50
Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer Andreea D. Stuparu, Joseph Capri, Catherine Meyer, Journal of Nuclear Medicine	2020	50
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer Giacomo Canesin, Susan Evans‐Axelsson, Rebecka Hellsten, European Urology UrologyMetastatic SpreadMedicineAnti-cancer AgentProstatic Disease	2015	49
Preclinical Characterization of 3β-(<i>N</i>-Acetyl <scp>l</scp>-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer Zilma Escobar, Anders Bjartell, Giacomo Canesin, Journal of Medicinal Chemistry	2016	35
Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors Ksenia Lisova, Maxim Sergeev, Susan Evans‐Axelsson, Nuclear Medicine and Biology Positron Emission TomographyEngineeringOncologic ImagingPotential Pet TracerClinical Imaging	2018	35
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer Kristina Witt, Susan Evans‐Axelsson, Andreas Lundqvist, Cancer Immunology Immunotherapy	2021	32
Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study Andreea D. Stuparu, Catherine Meyer, Susan Evans‐Axelsson, Theranostics	2020	27
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6 Oskar Vilhelmsson Timmermand, David Ulmert, Susan Evans‐Axelsson, EJNMMI Research	2014	23

Page 1